Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 1, 2003, Pages 65-70

  Vitale, Roxana G ^a   Meis, Jacques F G M ^b   Mouton, Johan W ^a   Verweij, Paul E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Amphotericin B; Nystatin; PAFE; Zygomycetes

Indexed keywords

AMPHOTERICIN B; NYSTATIN;

ABSIDIA; ANTIFUNGAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EXPOSURE; FUNGAL STRAIN; FUNGUS GROWTH; FUNGUS SPORE; IN VITRO STUDY; INCUBATION TIME; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; MUCOR; NONHUMAN; OPTICAL DENSITY; PRACTICE GUIDELINE; RHIZOPUS ORYZAE; SPECTROPHOTOMETRY; ZYGOMYCETES;

EID: 0037587275     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg285     Document Type: Article

References (23)

1. Platauf, A. P. (1885). Mycosis mucorina. Virchows Archiv: An International Journal of Pathology 102, 543-64.
2. Ribes, J. A., Vanover-Sams, C. L. & Baker, D. J. (2000). Zygomycetes in human disease. Clinical Microbiology Reviews 13, 236-301.
3. Sugar, A. M. (1992). Mucormycosis. Clinical Infectious Diseases 14, Suppl. 1, S126-9.
4. Dannaoui, E., Afeltra, J., Meis, J. F. et al. (2002). In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrobial Agents and Chemotherapy 46, 2708-11.
5. Vitale, R. G., Mouton, J. W., Afeltra, J. et al. (2002). Method for measuring postantifungal effect in Aspergillus species. Antimicrobial Agents and Chemotherapy 46, 1960-5.
6. Meletiadis, J., Meis, J. F., Mouton, J. W. et al. (2001). Analysis of growth characteristics of filamentous fungi in different nutrient media. Journal of Clinical Microbiology 39, 478-84.
7. Gunderson, S. M., Hoffman, H., Ernst, E. J. et al. (2000). In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect. Antimicrobial Agents and Chemotherapy 44, 2887-90.
8. Odenholt, I. (2001). Pharmacodynamic effects of subinhibitory antibiotic concentrations. International Journal of Antimicrobial Agents 17, 1-8.
9. Ernst, E. J., Klepser, M. E. & Pfaller, M. A. (2000). Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy 44, 1108-11.
10. Espinel-Ingroff, A., Barchiesi, F., Hazen, K. C. et al. (1998). Standardization of antifungal susceptibility testing and clinical relevance. Medical Mycology 36, 68-78.
11. Cormican, M. G. & Pfaller, M. A. (1996). Standardization of antifungal susceptibility testing. Journal of Medical Microbiology 38, 561-78.
12. Pfaller, M. A., Rinaldi, M. G., Galgiani, J. N. et al. (1990). Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrobial Agents and Chemotherapy 34, 1648-54.
13. National Committee for Clinical Laboratory Standards. (1998). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-forming Filamentous Fungi: Approved Standard M-38A. NCCLS, Wayne, PA, USA,
14. Rex, J. H., Cooper, C. R., Jr, Merz, W. G. et al. (1995). Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrobial Agents and Chemotherapy 39, 906-9.
15. Hamilton-Miller, J. M. (1973). Chemistry and biology of the polyene macrolide antibiotics. Bacteriological Reviews 37, 166-96.
16. Mehta, R. T., Hopfer, R. L., Gunner, L. A. et al. (1987). Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrobial Agents and Chemotherapy 31, 1897-900.
17. Groll, A. H., Mickiene, D., Werner, K. et al. (2000). Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits. Antimicrobial Agents and Chemotherapy 44, 950-7.
18. Andes, D. (2003). In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrobial Agents and Chemotherapy 47, 1179-86.
19. Khoo, S. H., Bond, J. & Denning, D. W. (1994). Administering amphotericin B - a practical approach. Journal of Antimicrobial Chemotherapy 33, 203-13.
20. Collette, N., van der Auwera, P., Lopez, A. P. et al. (1989). Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrobial Agents and Chemotherapy 33, 362-8.
21. Andes, D., Stamsted, T. & Conklin, R. (2001). Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrobial Agents and Chemotherapy 45, 922-6.
22. Dupont, B. (2002). Overview of the lipid formulations of amphotericin B. Journal of Antimicrobial Chemotherapy 49, Suppl. 1, 31-6.
23. Ellepola, A. N. & Samaranayake, L. P. (11999). The in vitro postantifungal effect of nystatin on Candida species of oral origin. Journal of Oral Pathology and Medicine 28, 112-6.